192 related articles for article (PubMed ID: 38360038)
1. Long-term safety and effectiveness of canakinumab in patients with monogenic autoinflammatory diseases: results from the interim analysis of the RELIANCE registry.
Kuemmerle-Deschner JB; Kallinich T; Henes J; Kortus-Götze B; Oommen PT; Rech J; Krickau T; Weller-Heinemann F; Horneff G; Janda A; Foeldvari I; Schuetz C; Dressler F; Borte M; Hufnagel M; Meier F; Fiene M; Andreica I; Weber-Arden J; Blank N
RMD Open; 2024 Feb; 10(1):. PubMed ID: 38360038
[TBL] [Abstract][Full Text] [Related]
2. Reasons for canakinumab initiation among patients with periodic fever syndromes: a retrospective medical chart review from the United States.
Hur P; Lomax KG; Ionescu-Ittu R; Manceur AM; Xie J; Cammarota J; Gautam R; Sanghera N; Kim N; Grom AA
Pediatr Rheumatol Online J; 2021 Sep; 19(1):143. PubMed ID: 34521444
[TBL] [Abstract][Full Text] [Related]
3. Systematic literature review of efficacy/effectiveness and safety of current therapies for the treatment of cryopyrin-associated periodic syndrome, hyperimmunoglobulin D syndrome and tumour necrosis factor receptor-associated periodic syndrome.
Kuemmerle-Deschner JB; Gautam R; George AT; Raza S; Lomax KG; Hur P
RMD Open; 2020 Jul; 6(2):. PubMed ID: 32723831
[TBL] [Abstract][Full Text] [Related]
4. Canakinumab treatment real world evidence in 3 monogenic periodic fever syndromes in 2009-2022: an interim analysis using the French JIR cohort database.
Koné-Paut I; Georgin-Lavialle S; Belot A; Jover M; Pouriel M; Lacoin L; Pillet P; Hentgen V
Arthritis Res Ther; 2024 Apr; 26(1):80. PubMed ID: 38589954
[TBL] [Abstract][Full Text] [Related]
5. Real-world safety and effectiveness of canakinumab in patients with tumour necrosis factor receptor-associated periodic syndrome or hyperimmunoglobulinaemia D syndrome: Interim results from post-marketing surveillance in Japan.
Hosono K; Matsumoto K; Shimbo M; Tsumiyama I; Kato C
Mod Rheumatol; 2023 Mar; 33(2):381-391. PubMed ID: 35575279
[TBL] [Abstract][Full Text] [Related]
6. Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes.
De Benedetti F; Gattorno M; Anton J; Ben-Chetrit E; Frenkel J; Hoffman HM; Koné-Paut I; Lachmann HJ; Ozen S; Simon A; Zeft A; Calvo Penades I; Moutschen M; Quartier P; Kasapcopur O; Shcherbina A; Hofer M; Hashkes PJ; Van der Hilst J; Hara R; Bujan-Rivas S; Constantin T; Gul A; Livneh A; Brogan P; Cattalini M; Obici L; Lheritier K; Speziale A; Junge G
N Engl J Med; 2018 May; 378(20):1908-1919. PubMed ID: 29768139
[TBL] [Abstract][Full Text] [Related]
7. Consensus protocols for the diagnosis and management of the hereditary autoinflammatory syndromes CAPS, TRAPS and MKD/HIDS: a German PRO-KIND initiative.
Hansmann S; Lainka E; Horneff G; Holzinger D; Rieber N; Jansson AF; Rösen-Wolff A; Erbis G; Prelog M; Brunner J; Benseler SM; Kuemmerle-Deschner JB
Pediatr Rheumatol Online J; 2020 Feb; 18(1):17. PubMed ID: 32066461
[TBL] [Abstract][Full Text] [Related]
8. International Retrospective Chart Review of Treatment Patterns in Severe Familial Mediterranean Fever, Tumor Necrosis Factor Receptor-Associated Periodic Syndrome, and Mevalonate Kinase Deficiency/Hyperimmunoglobulinemia D Syndrome.
Ozen S; Kuemmerle-Deschner JB; Cimaz R; Livneh A; Quartier P; Kone-Paut I; Zeft A; Spalding S; Gul A; Hentgen V; Savic S; Foeldvari I; Frenkel J; Cantarini L; Patel D; Weiss J; Marinsek N; Degun R; Lomax KG; Lachmann HJ
Arthritis Care Res (Hoboken); 2017 Apr; 69(4):578-586. PubMed ID: 27723279
[TBL] [Abstract][Full Text] [Related]
9. Monogenic Periodic Fever Syndromes: Treatment Options for the Pediatric Patient.
Ozen S; Demir S
Paediatr Drugs; 2017 Aug; 19(4):303-311. PubMed ID: 28497352
[TBL] [Abstract][Full Text] [Related]
10. Long-term safety and effectiveness of canakinumab therapy in patients with cryopyrin-associated periodic syndrome: results from the β-Confident Registry.
Walker UA; Tilson HH; Hawkins PN; Poll TV; Noviello S; Levy J; Vritzali E; Hoffman HM; Kuemmerle-Deschner JB;
RMD Open; 2021 May; 7(2):. PubMed ID: 34001647
[TBL] [Abstract][Full Text] [Related]
11. Current treatment options for monogenic periodic fever syndromes - the role of interleukin 1 inhibitors.
Milota T; Malcová H; Střížová Z; Cebecauerová D; Horváth R
Cas Lek Cesk; 2022; 161(1):3-10. PubMed ID: 35354288
[TBL] [Abstract][Full Text] [Related]
12. Evidence-based provisional clinical classification criteria for autoinflammatory periodic fevers.
Federici S; Sormani MP; Ozen S; Lachmann HJ; Amaryan G; Woo P; Koné-Paut I; Dewarrat N; Cantarini L; Insalaco A; Uziel Y; Rigante D; Quartier P; Demirkaya E; Herlin T; Meini A; Fabio G; Kallinich T; Martino S; Butbul AY; Olivieri A; Kuemmerle-Deschner J; Neven B; Simon A; Ozdogan H; Touitou I; Frenkel J; Hofer M; Martini A; Ruperto N; Gattorno M;
Ann Rheum Dis; 2015 May; 74(5):799-805. PubMed ID: 25637003
[TBL] [Abstract][Full Text] [Related]
13. Canakinumab in colchicine resistant familial Mediterranean fever and other pediatric rheumatic diseases.
Çakan M; Karadağ ŞG; Ayaz NA
Turk J Pediatr; 2020; 62(2):167-174. PubMed ID: 32419407
[TBL] [Abstract][Full Text] [Related]
14. Dosage Considerations for Canakinumab in Children With Periodic Fever Syndromes.
Zhuang L; Chen J; Yu J; Marathe A; Sahajwalla C; Borigini M; Maynard J; Burckart GJ; Wang Y
Clin Pharmacol Ther; 2019 Sep; 106(3):557-567. PubMed ID: 30447083
[TBL] [Abstract][Full Text] [Related]
15. Rapid and Sustained Long-Term Efficacy and Safety of Canakinumab in Patients With Cryopyrin-Associated Periodic Syndrome Ages Five Years and Younger.
Brogan PA; Hofer M; Kuemmerle-Deschner JB; Koné-Paut I; Roesler J; Kallinich T; Horneff G; Calvo Penadés I; Sevilla-Perez B; Goffin L; Lauwerys BR; Lachmann HJ; Uziel Y; Wei X; Laxer RM
Arthritis Rheumatol; 2019 Nov; 71(11):1955-1963. PubMed ID: 31161734
[TBL] [Abstract][Full Text] [Related]
16. Validation of the auto-inflammatory diseases activity index (AIDAI) for hereditary recurrent fever syndromes.
Piram M; Koné-Paut I; Lachmann HJ; Frenkel J; Ozen S; Kuemmerle-Deschner J; Stojanov S; Simon A; Finetti M; Sormani MP; Martini A; Gattorno M; Ruperto N;
Ann Rheum Dis; 2014 Dec; 73(12):2168-73. PubMed ID: 24026675
[TBL] [Abstract][Full Text] [Related]
17. Autoinflammatory Diseases with Periodic Fevers.
Sag E; Bilginer Y; Ozen S
Curr Rheumatol Rep; 2017 Jul; 19(7):41. PubMed ID: 28631068
[TBL] [Abstract][Full Text] [Related]
18. Retrospective case series describing the efficacy, safety and cost-effectiveness of a vial-sharing programme for canakinumab treatment for paediatric patients with cryopyrin-associated periodic syndrome.
Elmi AA; Wynne K; Cheng IL; Eleftheriou D; Lachmann HJ; Hawkins PN; Brogan P
Pediatr Rheumatol Online J; 2019 Jul; 17(1):36. PubMed ID: 31287007
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of canakinumab in Japanese patients with phenotypes of cryopyrin-associated periodic syndrome as established in the first open-label, phase-3 pivotal study (24-week results).
Imagawa T; Nishikomori R; Takada H; Takeshita S; Patel N; Kim D; Lheritier K; Heike T; Hara T; Yokota S
Clin Exp Rheumatol; 2013; 31(2):302-9. PubMed ID: 23380020
[TBL] [Abstract][Full Text] [Related]
20. Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes.
Kuemmerle-Deschner JB; Hachulla E; Cartwright R; Hawkins PN; Tran TA; Bader-Meunier B; Hoyer J; Gattorno M; Gul A; Smith J; Leslie KS; Jiménez S; Morell-Dubois S; Davis N; Patel N; Widmer A; Preiss R; Lachmann HJ
Ann Rheum Dis; 2011 Dec; 70(12):2095-102. PubMed ID: 21859692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
